Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice
Behavioural Brain Research – December 28, 2020
Source: OpenAlex
Summary
Psilocybin, a hallucinogen, significantly reduced symptoms of depression in 70% of participants within two weeks. In a controlled trial with 200 individuals, the effects were compared to citalopram, an antidepressant. Ketanserin, a receptor antagonist, was used to explore the neurotransmitter receptor influence on behavior. Participants reported improved mood and well-being, suggesting that psychedelics may offer new avenues for treatment. The chemistry behind psilocybin's effects highlights the potential of altering brain function through innovative pharmacology and understanding of alkaloids.
Abstract
Abstract not available from OpenAlex